Products Evolocumab was approved in the EU and US in 2015 and in many countries in 2016 in the form of a solution for injection (Repatha). Structure and properties Evolocumab is a human IgG2 monoclonal antibody with a molecular mass of 141.8 kDa. It is produced by biotechnological methods. Effects Evolocumab (ATC C10AX13) has lipid-lowering … Evolocumab
Products Lipid-lowering agents are mainly sold as tablets and capsules as monopreparations and combination preparations. Some other dosage forms exist, such as granules and injectables. Statins have established themselves as the most important group at present. Structure and properties The chemical structure of lipid-lowering agents is inconsistent. However, within the class, groups with comparable structures … Lipid-Lowering Agents
Products Alirocumab was approved in the United States and EU in 2015 and in many countries in 2016 as the first agent in the group of PCSK9 inhibitors in the form of a solution for injection (Praluent). Structure and properties Alirocumab is an IgG1 monoclonal antibody with a molecular mass of 146 kDa. Effects Alirocumab … Alirocumab
Products Alirocumab was approved in the United States in 2015 as the first agent in the group of PCSK9 inhibitors in the form of a solution for injection (Praluent). Evolocumab (Repatha) followed as the second agent in the EU, also in 2015. Structure and properties PCSK9 inhibitors to date are monoclonal antibodies that must be … PCSK9 Inhibitors
